NCT07490327

Assessment of Dutasteride Topical Solution in Male Androgenetic Alopecia

A Randomized, Open-label, Single and Multiple-dose, Parallel-design Phase 1/2a Clinical Trial to Evaluate the Pharmacokinetics/Pharmacodynamics and Safety of AD-303A and Oral Administration of AD-3031 in Male Androgenetic Alopecia Patients

• Status: Not Yet Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Moogene Medi Co., Ltd · Industry
• Sex: Male
• Age: 19 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This is a randomized, open-label phase 1/2a study designed to evaluate the pharmacokinetics, pharmacodynamics, and safety of AD-303A (topical formulation) and AD-3031 in male patients with androgenetic alopecia. The study aims to compare pharmacological characteristics and safety profiles to support dose selection for further clinical development.

Conditions

• Androgenetic Alopecia

Interventions

Type	Name	Description
DRUG	AD-303A	Topical AD-303A applied to the scalp according to the study protocol.
DRUG	AD-3031	Oral AD-3031 administered according to the study protocol.

Timeline

• Start date: 2026-04-01
• Primary completion: 2026-09-01
• Completion: 2026-12-01
• First posted: 2026-03-24
• Last updated: 2026-03-24

Locations

1 site across 1 country: South Korea